• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

EASL HCC 峰会:肝癌管理。

EASL HCC summit: liver cancer management.

机构信息

Dipartimento di Gastroenterologia-UO Gastroenterologia e Malattie del Ricambio, Azienda Ospedaliero Universitaria Pisana, Ospedale Cisanello Via Paradisa 2, 56124 Pisa, Italy.

出版信息

Future Oncol. 2014 May;10(7):1129-32. doi: 10.2217/fon.14.68.

DOI:10.2217/fon.14.68
PMID:24947253
Abstract

EASL HCC Summit, Geneva, Switzerland, 13-16 February 2014. The European Association for the Study of the Liver (EASL) organized the 2014 EASL HCC Summit in Geneva, Switzerland. We discuss here the most interesting and provocative contents from the clinical program of the summit. The objective of this segment was to provide an in-depth review on the different management issues related to early detection, diagnosis and treatment of hepatocellular carcinoma, and, in addition, to highlight the ways of dealing with such an important and rapidly involving field.

摘要

2014 年 2 月 13 日至 16 日,瑞士日内瓦举行了 EASL HCC 峰会。欧洲肝脏研究协会(EASL)在瑞士日内瓦组织了 2014 年 EASL HCC 峰会。在这里,我们将讨论峰会临床项目中最有趣和最具争议的内容。本节的目的是深入回顾与肝细胞癌的早期发现、诊断和治疗相关的不同管理问题,并强调处理这一重要且快速发展领域的方法。

相似文献

1
EASL HCC summit: liver cancer management.EASL HCC 峰会:肝癌管理。
Future Oncol. 2014 May;10(7):1129-32. doi: 10.2217/fon.14.68.
2
Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017.来自欧洲肝脏研究学会的报告:HCC 峰会,瑞士日内瓦,2017 年 2 月 2 日至 5 日。
Future Oncol. 2017 Jun;13(15):1297-1300. doi: 10.2217/fon-2017-0133. Epub 2017 Jun 7.
3
Advances in Hepatocellular Carcinoma.肝细胞癌的进展
Clin Liver Dis. 2020 Nov;24(4):xiii-xiv. doi: 10.1016/j.cld.2020.08.014.
4
Management of HCC.肝癌的治疗。
J Hepatol. 2012;56 Suppl 1:S75-87. doi: 10.1016/S0168-8278(12)60009-9.
5
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.多学科策略改善肝细胞癌治疗结局:欧洲视角。
Eur J Gastroenterol Hepatol. 2013 Jun;25(6):639-51. doi: 10.1097/MEG.0b013e32835e33bb.
6
Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.实体瘤反应评估标准(RECIST)标准优于欧洲肝脏研究协会(EASL)标准,在肝癌患者接受肝移植前经动脉化疗栓塞治疗 1 个月随访时,可预测长期生存。
J Vasc Interv Radiol. 2013 Jun;24(6):805-12. doi: 10.1016/j.jvir.2013.01.499. Epub 2013 Apr 4.
7
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南:肝细胞癌的管理
Eur J Cancer. 2012 Mar;48(5):599-641. doi: 10.1016/j.ejca.2011.12.021.
8
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.肝细胞癌的诊断、分期及管理:美国肝病研究协会2018年实践指南
Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913.
9
European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?2014年欧洲肝脏研究协会肝细胞癌峰会:旧问题,新(或很少)答案?
Future Oncol. 2014 Aug;10(10):1719-21. doi: 10.2217/fon.14.102.
10
Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology.日本肝细胞癌的管理:日本肝脏学会提出的基于共识的临床实践手册
Oncology. 2007;72 Suppl 1:2-15. doi: 10.1159/000111702. Epub 2007 Dec 13.

引用本文的文献

1
Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.肝细胞癌患者中药物洗脱微球经动脉化疗栓塞术与传统经动脉化疗栓塞术治疗反应的比较
Cureus. 2023 Jul 11;15(7):e41701. doi: 10.7759/cureus.41701. eCollection 2023 Jul.
2
Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy.非手术复发性肝细胞癌的放射学表现:从局部区域治疗到免疫治疗。
World J Gastroenterol. 2023 Mar 21;29(11):1669-1684. doi: 10.3748/wjg.v29.i11.1669.
3
Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC.
严重维生素D缺乏会增加肝硬化患者的死亡率,无论是否存在肝癌。
In Vivo. 2019 Jan-Feb;33(1):177-182. doi: 10.21873/invivo.11456.
4
Screening therapeutic targets of ribavirin in hepatocellular carcinoma.筛选利巴韦林在肝细胞癌中的治疗靶点。
Oncol Lett. 2018 Jun;15(6):9625-9632. doi: 10.3892/ol.2018.8552. Epub 2018 Apr 20.
5
Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients.肝细胞癌患者对索拉非尼临床及影像学反应的评估
World J Hepatol. 2015 Jan 27;7(1):33-9. doi: 10.4254/wjh.v7.i1.33.